Ikena Oncology, formerly known as Kyn Therapeutics, submitted its S-1 paperwork Friday penciling in a $100 million to jump to Nasdaq. The company’s lead in-house candidate has not yet reached the clinic, but it’s working with BMS and Merck on a couple tumor microenvironment programs that have already hit Phase I.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,